Aldosterone and the hypertensive kidney: Its emerging role as a mediator of progressive renal dysfunction: A paradigm shift

Journal of Hypertension

Volumn 19, Issue 5, 2001, Pages 829-842

  Epstein, Murray ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Aldosterone receptor antagonist; End stage renal disease (ESRD); Hypertensive renal disease; Plasminogen activator inhibitor 1 (PAI 1); Reactive oxygen species (ROS)

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ALDOSTERONE BLOOD LEVEL; ANIMAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG INDUCED DISEASE; ENDOTHELIUM LESION; ESSENTIAL HYPERTENSION; FIBRINOLYSIS; FIBROSIS; GLOMERULOSCLEROSIS; HUMAN; HYPERKALEMIA; IMPOTENCE; KIDNEY FAILURE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR;

EID: 0035022922     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200105000-00001     Document Type: Review

References (88)

1. 1 United States Renal Data System. Excerpts from United States Renal Data System 1999 Annual Data Report. Am J Kidney Dis 1999; 34 (suppl 1):S1-S176.
2. 2 United States Renal Data System. USRDS 1997 Annual Report. Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health; 1997. pp. 21-34.
3. 3 The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
4. 4 Klag MJ, Whelton PK, Randall SL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13-18.
5. 5 Mroczek WJ, Davidov M, Gavrilovich L, Finnerty FA Jr. The value of aggressive therapy in the hypertensive patient with azotemia. Circulation 1989; 40:893-904.
6. 6 Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25:587-594.
7. 7 Pettinger WA, Lee HO, Reisch J, Mitchell HC. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension 1989; 13:766-772.
8. 8 Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 820:684-688.
9. 9 Shulman NB, Ford CE, Hall DW, Blaufox MD, Simon D, Langford HG, et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from Hypertension Detection and Follow-up Program. Hypertension 1989; 13 (suppl 1):180-193.
10. 10 Perneger TV, Nieto FJ, Whelton PK, Klag MJ, Comstock GW, Szklo M. A prospective study of blood pressure and serum creatinine. Results from the 'Clue' study and the ARIC study. JAMA 1993; 269:488-493.
11. 11 Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 1990; 150:2073-2076.
12. 12 Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD, MRFIT Research Group. Renal function change in hypertensive members of the multiple risk factor intervention trial. JAMA 1992; 268:3085-3091.
13. 13 Iseki K, Ikemiya Y, Fukiyama K. Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney Int 1996; 49 (suppl): 569-671.
14. 14 Tomson CR, Peterson K, Heagerty AM. Does treated essential hypertension result in renal impairment? A cohort study. J Hum Hypertens 1991; 5: 189-192.
15. 15 Siewert-Delle A, Ljungman S, Andersson OK, Wilhelmsen L. Does treated primary hypertension lead to end-stage renal disease: a 20-year follow-up of the Primary Prevention Study in Göteberg, Sweden. Nephrol Dial Transplant 1998; 13:3084-3090.
16. 16 Harvey JM, Howie AJ, Lee SJ, Newbold KM, Adu D, Michael J, et al. Renal biopsy findings in hypertensive patients with proteinuria. Lancet 1992; 340:1435-1436.
17. 17 Innes A, Johnston PA, Morgan AG, Davison AM, Burden RP. Clinical features of benign hypertensive nephrosclerosis at time of renal biopsy. Quart J Med 1993; 88:271-275.
18. 18 Zucchelli P, Zuccala A. The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist's view. Am J Kidney Dis 1993; 21 (suppl 2): 87-91.
19. 19 Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49:578-597.
20. 20 Ibrahim HN, Rosenberg ME, Hostetter TH. Role of renin-angiotensin-aldosterone system in the progression of renal disease: a critical review. Semin Nephrol 1997; 17:431-440.
21. 21 Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51:2-15.
22. 22 The GISEN Study Group. Randomized placebo-controlled trial of effect of ramipril on decline in GFR and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group. Lancet 1997; 349: 1857-1863.
23. 23 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
24. 24 Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Koss M, Cote LJ, et al. Malignant hypertension resulting from deoxycortisone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 1975; 36:300-309.
25. 25 Greene E, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98:1063-1068.
26. 26 Horiuchi M, Nishiyama H, Hama J, Takenaka T, Kondo H, Kino H, et al. Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol 1993; 264:F286-F291.
27. 27 Rocha R, Chander PN, Zuckerman A, Stier CT. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33:232-237.
28. 28 Quan ZY, Walser M, Hill GS. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 1992; 41:326-333.
29. 29 Ullian ME, Islam MM, Robinson CJ, Fitzgibbon WR, Tobin ET, Paul RV. Resistance to mineralocorticoids in Wistar-Furth rats. Am J Physiol 1997; 272:H1454-H1461.
30. 30 Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339:1448-1456.
31. 31 Gansevoort RT, Navis GJ, Wapstra FH, de Jong PE, de Zeeuw O. Proteinuria and progression of renal disease: therapeutic implications. Curr Opin Nephrol Hypertens 1997; 6:133-140.
32. 32 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-717.
33. 33 Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
34. 34 Ritz E, Orth S, Weinreich T, Wagner J. Systemic hypertension versus intraglomerular hypertension in progression. Kidney Int 1994; 45:438-442.
35. 35 Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 1987; 31:752-759.
36. 36 Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1987; 352:1252-1256.
37. 37 Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978; 14:228-235.
38. 38 Hene RJ, Boer P, Koomans HA, Dorhout Mees EJ. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21:98-101.
39. 39 Foster RH, MacFarlane CH, Bustamante MO. Recent progress in understanding aldosterone secretion. Gen Pharmacol 1997; 28:647-651.
40. 40 Fuller PJ. Aldosterone's effects and mechanism of action. Curr Opin Endocrinol Diabetes 1997; 4:218-224.
41. 41 Luetscher JA Jr, Neher JP, Wettstein A. Isolation of crystalline aldosterone from the urine of a nephrotic patient. Experientia 1954; 10:456-458.
42. 42 Farquiharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin l/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101:594-597.
43. 43 Duprez D, De Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Reports 2000; 2:327-334.
44. 44 Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31:451-458.
45. 45 Hostetter TH, Kren S, Ibrahim HN. Mineralocorticoid receptor blockade in the remnant kidney model [abstract]. J Am Soc Nephrol 1999; 10:85A.
46. 46 Brilla CG, Weber KT. Mineralocorticoid excess, dietary medium and myocardial fibrosis. J Lab Clin Med 1992; 120:893-901.
47. 47 Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992; 20:67-73.
48. 48 Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93:2578-2583.
49. 49 Bonvalet JP, Alfaidy N, Farman N, Lombes M. Aldosterone: intracellular receptors in human heart. Eur Heart J 1995; 16 (suppl N):92-97.
50. 50 Kornel L. Colocalization of 11b-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 1994; 7:100-103.
51. 51 Lombes M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 1992; 71:503-510.
52. 52 Tanaka J, Fujita H, Matsuda S, Toku K, Sakanaka M, Maeda N. Glucocorticoid-and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Glia 1997; 20:23-37.
53. 53 Hatakeyama H, Miyamori L, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 289:24318-24320.
54. 54 Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and carticosterone in the rat. Physiological regulation. J Biol Chem 1998; 273:4883-4891.
55. 55 Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effect of adding spironolactone to an ACE inhibitor in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995; 78:1259-1265.
56. + channels. Steroids 1995; 60:114-119.
57. 57 Weber MA, Purdy RE. Catecholamine mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 1982; 30:2009-2017.
58. 58 Stier CT, Chander PN, Zuckerman A, Rocha R. Nonepithelial effects of aldosterone. Curr Opin Endocrinol Diabetes 1998; 5:211-216.
59. 59 Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336-344.
60. 60 Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58:1219-1227.
61. 61 Stier C Jr, Zuckerman A, Harashima H, Chander P. Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone spontaneously hypertensive rats [abstract P4.03]. Proceedings of the International Society of Hypertension; 23 August 2000; Chicago, IL.
62. 62 Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 2000; 35: 1078-1084.
63. 63 Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992; 20:3-16.
64. 64 Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 2000; 58: 251-259.
65. 65 Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-I. Hypertension 1998; 32:965-971.
66. 66 Nicoletti A, Heudes D, Hinglais N, Appay MD, Philippe M, Sassy-Prigent C, et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension 1995; 26:101-111.
67. 67 Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17:1152-1156.
68. 68 Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71:12A-16A.
69. 69 MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35:30-34.
70. 70 Rocha R, Chander PN, Zuckerman A, Stier CT. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rates [abstract]. Hypertension 1998; 32:598.
71. 71 Pitt B. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9:145-149.
72. 72 Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Cardiac Failure 1996; 2:47-54.
73. 73 Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnaru B. Evidence of partial escape of RAA blockade in patients with acute MI treated with ACE inhibitors. J Clin Pharmacol 1993; 33:40-45.
74. 74 Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentrations of aldosterone during long term angiotensin II suppression. J Endocrinol 1981; 91:457-465.
75. 75 Sato A, Suzuki Y, Shibata H, Saruta T. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res 2000; 23:25-31.
76. 76 Mantero F, Opocher G, Rocco S, Carpene G, Armanini D. Long-term treatment of mineralocorticoid excess syndromes. Steroids 1995; 60: 81-86.
77. 77 Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60:820-825.
78. 78 de Gasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P, Menard J. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989; 32:223-227.
79. 79 Helfer EL, Miller JL, Rose LI. Side-effects of spiranolactone therapy in the hirsute woman. J Clin Endocrin Metab 1988; 66:208-211.
80. 80 Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Derm 1988; 118:687-691.
81. 81 Rabasseda X, Silvestre J, Castan̄er J. Eplerenone. Drugs Future 1999; 24:488-501.
82. 82 Hasan F, Weinberg EO, Delyani J, Frierdich G, Converso K, Douglas PS, et al. Aldosterone and cardiac hypertrophy: effects of eplerenone on LV function and hypertrophic remodeling in LV pressure overload [abstract]. Circulation 1999; 100 (suppl I):I565.
83. 83 Epstein M, Alexander JC, Roniker B. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension [abstract]. Hypertension 1999; 33:1075.
84. 84 Pitt B, Roniker B. Eplerenone, a novel selective aldosterone receptor antagonist (SARA): a dose finding study in patients with heart failure [abstract]. J Am Coll Cardiol 1999; 33 (suppl A):188A-189A.
85. 85 Weidmann P, Demyttenaere-Bursztein S, Maxwell MH, Delima J. Effect of aging on plasma renin and aldosterone in normal man. Kidney Int 1975; 8:325-333.
86. 86 Epstein M. Aging and the kidney. J Am Soc Nephrol 1996; 7:1106-1122.
87. 87 Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19:403-418.
88. 88 Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997; 29:45-48.